FIELD: biotechnology.
SUBSTANCE: following is described: a group of inventions including a compound for activating NK cells, a composition for use in inducing proliferation of NK cells, a method of inducing NK-mediated destruction of a target cell in a subject, a method of stimulating the proliferation of NK cells in vivo, a method of inhibiting the growth of cancer cells in a subject, a method of stimulating secretion of inflammatory cytokines by NK cells in vivo, and a method of treating acute myeloid leukemia (AML) in a subject.
EFFECT: invention expands the arsenal of means for activating NK cells.
26 cl, 53 dwg, 1 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC COMPOUNDS AND METHODS | 2016 |
|
RU2770001C2 |
| CD33, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2820603C2 |
| GLYCAN-DEPENDENT IMMUNOTHERAPY MOLECULES | 2016 |
|
RU2754661C2 |
| POLYVALENT BINDING PROTEINS FOR ACTIVATION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC APPLICATION FOR TREATMENT OF MALIGNANT NEOPLASM | 2018 |
|
RU2809125C2 |
| TRUNCATED CHIMERIC RECEPTORS NKG2D AND THEIR WAYS OF USE IN IMMUNOTHERAPY USING NATURAL KILLER CELLS | 2018 |
|
RU2830556C2 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| TREATING CANCER USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANIZED ANTI-EGFRvIII ANTIBODY | 2014 |
|
RU2831418C2 |
| TREATING CANCER USING A CHIMERIC ANTIGENIC CLL-1 RECEPTOR | 2015 |
|
RU2741120C2 |
| BCMA, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2805254C2 |
